Source: American heart journal. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, INFECÇÕES POR HIV, HIPERCOLESTEROLEMIA, DISLIPIDEMIAS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, ESTATINAS, ENZIMAS PROTEOLÍTICAS, ESTUDOS MULTICÊNTRICOS
ABNT
BOCCARA, Franck et al. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, v. 220, p. 203-212, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2019.11.004. Acesso em: 18 out. 2024.APA
Boccara, F., Kumar, P., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, 220, 203-212. doi:10.1016/j.ahj.2019.11.004NLM
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 out. 18 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004Vancouver
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 out. 18 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004